Last checked at 23 Jul 2021 13:35
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that its Annual Report and Accounts for the year ended 31 March 2021 and Notice of Annual General Meeting ("AGM") will be posted to shareholders later today and will be available in full to download from the Company's website (www.nuformix.com) shortly.
In accordance with the Listing Rule 9.6.1, a copy of these documents has been uploaded to National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The AGM will be held at Orega, 70 Gracechurch Street, London, EC3V 0HR on Tuesday, 24 August 2021 at 10.00am.
Shareholders should read the Notice of AGM for further details of arrangements for attendance at the AGM and voting.
Enquiries:
Nuformix plc | +44 (0)1223 627222 | |||
Dr Anne Brindley, CEO | ||||
Allenby Capital Limited | +44 (0)203 328 5656 | |||
Nick Athanas / George Payne (Corporate Finance) | ||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) | ||||
Walbrook PR | ||||
Anna Dunphy / Paul McManus / Kiki Zaccagnini | +44 (0)207 933 8780 nuformix@walbrookpr.com | |||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.